Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Yoonsun YoonDepartment of Pediatrics, Korea University College of Medicine, Seoul 02841, Republic of Korea.ORCID 0000-0003-0187-3922
Hye-Kyung ChoDepartment of Pediatrics, Gachon University College of Medicine, Incheon 21565, Republic of Korea.ORCID 0000-0003-0990-1350
Ki Hwan KimDepartment of Pediatrics, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 21431, Republic of Korea.ORCID 0000-0001-6145-3909
Su Eun ParkDepartment of Pediatrics, Pusan National University College of Medicine, Yangsan 50612, Republic of Korea.ORCID 0000-0001-5860-821X
Yae-Jean KimDepartment of Pediatrics, School of Medicine, Sungkyunkwan University, Seoul 06351, Republic of Korea.ORCID 0000-0002-8367-3424
Jina LeeDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.ORCID 0000-0002-3435-251X
Hwang Min KimDepartment of Pediatrics, Yonsei University, Wonju College of Medicine, Wonju 26426, Republic of Korea.ORCID 0000-0002-0329-1371
Nam Hee KimDepartment of Pediatrics, Inje University Ilsan Paik Hospital, Goyang 10380, Republic of Korea.ORCID 0000-0002-1793-1392
Dae Sun JoDepartment of Pediatrics, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea.ORCID 0000-0002-3141-9539
Eun Young ChoDepartment of Pediatrics, Chungnam National University Hospital, Daejeon 35015, Republic of Korea.ORCID 0000-0002-2286-4593
Seon Hee ShinDepartment of Pediatric & Adolescent Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong 18450, Republic of Korea.ORCID 0000-0003-3324-4282
Jong-Hyun KimDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0001-8641-7904
Ji Hwa RyuDepartment of R&D, SK Bioscience, Seongnam 13494, Republic of Korea.ORCID 0000-0001-5934-0905
Ho Keun ParkDepartment of R&D, SK Bioscience, Seongnam 13494, Republic of Korea.ORCID 0009-0008-7124-9969
Yoonyeong LeeDepartment of R&D, SK Bioscience, Seongnam 13494, Republic of Korea.ORCID 0000-0002-1587-4961
Yun-Kyung KimDepartment of Pediatrics, Korea University College of Medicine, Seoul 02841, Republic of Korea.ORCID 0000-0003-4396-8671
Funding
SK bioscience (Seongnam, Republic of Korea) Protocol No. NBP607-QIV-301
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial. · full record | OpenQuestion